Skip to main content

In Brief This Week: Quest Diagnostics, Meridian Bioscience, Fortress Diagnostics, and More

NEW YORK (360Dx) – Quest Diagnostics has completed its acquisitions of the laboratory businesses of Med Fusion and Clear Point. Both are based in Lewisville, Texas and will form Quest’s first national center of excellence in precision diagnostics for oncology.


Meridian Bioscience announced this week that it has opened a wholly foreign-owned enterprise (WFOE) in Beijing, China called Meridian Bioscience Beijing. Meridian opened a representative office in Beijing in 2015, and this office has now been transitioned to a WFOE to better serve the firm's Chinese customers. Through the WFOE, Meridian said it now has a local sales, marketing, and distribution function for research and IVD customers in China.


Fortress Diagnostics will manufacture Irish firm 3N Diagnostics' Avisio FOXC1 breast cancer test. The test detects a biomarker that 3N said is unique to basal-like breast cancer, adding the condition has been a challenge to diagnose at the time of initial breast cancer diagnosis.


StoneCalibre said that an unnamed affiliate has completed its acquisition of Alpha-Tec Systems, a Vancouver, Washington-based provider of in vitro diagnostic products used by clinical laboratories. The firm, founded in 1979 provides digestion, decontamination, neutralization, and other sample preparation products for mycobacteria diagnostics. The terms of the deal were not disclosed. StoneCalibre did not respond to a request for comment.


SQI Diagnostics has signed a contract with an unnamed biotechnology company to commercialize a custom multiplexed assay for that firm's blood disorder drug programs. The biotech firm is based in Waltham, Massachusetts. Terms of the deal were not disclosed.


DermTech said that the American Medical Association has granted the firm category 1, tier 2 molecular pathology procedure codes related to its test for detecting melanoma-related gene expression. The firm has secured the CPT code for LINC and PRAME, the primary genes included in DermTech's noninvasive biopsy and gene expression test for skin cancer. The genes will be added to the approved list for CPT code 81401 by the AMA as of July 1.


Agilent Technologies said in a document filed with the US Securities and Exchange Commission it has entered into an amendment to a credit agreement originally reached in 2014. Under the amendment, the commitments under a five-year credit facility increased by $300 million to a new total of $1 billion. The original facility was for $400 million. In 2015, the commitments under the facility increased by $300 million.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.